Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-014321
Filing Date
2025-02-14
Accepted
2025-02-14 16:30:31
Documents
55
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0230774-10q_citius.htm   iXBRL 10-Q 487349
2 CERTIFICATION ea023077401ex31-1_citius.htm EX-31.1 9595
3 CERTIFICATION ea023077401ex31-2_citius.htm EX-31.2 9659
4 CERTIFICATION ea023077401ex32-1_citius.htm EX-32.1 4076
  Complete submission text file 0001213900-25-014321.txt   3793242

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctxr-20241231.xsd EX-101.SCH 42014
6 XBRL CALCULATION FILE ctxr-20241231_cal.xml EX-101.CAL 31268
7 XBRL DEFINITION FILE ctxr-20241231_def.xml EX-101.DEF 184279
8 XBRL LABEL FILE ctxr-20241231_lab.xml EX-101.LAB 351083
9 XBRL PRESENTATION FILE ctxr-20241231_pre.xml EX-101.PRE 198463
58 EXTRACTED XBRL INSTANCE DOCUMENT ea0230774-10q_citius_htm.xml XML 358116
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-38174 | Film No.: 25629669
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)